Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

N-Acetylglucosamine-1-Phosphate Transferase, WecA, as a Validated Drug Target in Mycobacterium tuberculosis.

Huszár S, Singh V, Polčicová A, Baráth P, Barrio MB, Lagrange S, Leblanc V, Nacy CA, Mizrahi V, Mikušová K.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01310-17. doi: 10.1128/AAC.01310-17. Print 2017 Nov.

2.

Tuberculosis - drugs in the 2016 development pipeline.

Laughon BE, Nacy CA.

Nat Rev Dis Primers. 2017 Mar 9;3:17015. doi: 10.1038/nrdp.2017.15. No abstract available.

PMID:
28276432
3.

Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.

Heinrich N, Dawson R, du Bois J, Narunsky K, Horwith G, Phipps AJ, Nacy CA, Aarnoutse RE, Boeree MJ, Gillespie SH, Venter A, Henne S, Rachow A, Phillips PP, Hoelscher M, Diacon AH; Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA); Pan African Consortium for the Evaluation of Antituberculosis Antibiotics PanACEA.

J Antimicrob Chemother. 2015 May;70(5):1558-66. doi: 10.1093/jac/dku553. Epub 2015 Jan 27.

PMID:
25630641
4.

Optimization of a nucleic acid-based reporter system to detect Mycobacterium tuberculosis antibiotic sensitivity.

Mulvey MC, Lemmon M, Rotter S, Lees J, Einck L, Nacy CA.

Antimicrob Agents Chemother. 2015 Jan;59(1):407-13. doi: 10.1128/AAC.03135-14. Epub 2014 Nov 3.

5.

Therapeutic efficacy of SQ641-NE against Mycobacterium tuberculosis.

Nikonenko B, Reddy VM, Bogatcheva E, Protopopova M, Einck L, Nacy CA.

Antimicrob Agents Chemother. 2014;58(1):587-9. doi: 10.1128/AAC.01254-13. Epub 2013 Oct 21.

6.

Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.

Sacksteder KA, Protopopova M, Barry CE 3rd, Andries K, Nacy CA.

Future Microbiol. 2012 Jul;7(7):823-37. doi: 10.2217/fmb.12.56. Review.

7.

Generation of a novel nucleic acid-based reporter system to detect phenotypic susceptibility to antibiotics in Mycobacterium tuberculosis.

Mulvey MC, Sacksteder KA, Einck L, Nacy CA.

MBio. 2012 Mar 13;3(2). pii: e00312-11. doi: 10.1128/mBio.00312-11. Print 2012.

8.

SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro.

Reddy VM, Dubuisson T, Einck L, Wallis RS, Jakubiec W, Ladukto L, Campbell S, Nacy CA.

J Antimicrob Chemother. 2012 May;67(5):1163-6. doi: 10.1093/jac/dkr589. Epub 2012 Jan 17.

PMID:
22258923
9.

Chemical modification of capuramycins to enhance antibacterial activity.

Bogatcheva E, Dubuisson T, Protopopova M, Einck L, Nacy CA, Reddy VM.

J Antimicrob Chemother. 2011 Mar;66(3):578-87. doi: 10.1093/jac/dkq495. Epub 2010 Dec 23.

10.

In vitro antimicrobial activities of capuramycin analogues against non-tuberculous mycobacteria.

Dubuisson T, Bogatcheva E, Krishnan MY, Collins MT, Einck L, Nacy CA, Reddy VM.

J Antimicrob Chemother. 2010 Dec;65(12):2590-7. doi: 10.1093/jac/dkq372. Epub 2010 Oct 14.

11.

Anti-tuberculosis drug therapy in mice of different inbred strains.

Nikonenko BV, Einck L, Nacy CA.

Infect Genet Evol. 2010 Oct;10(7):1151-4. doi: 10.1016/j.meegid.2010.07.014. Epub 2010 Jul 22.

PMID:
20655396
12.

In vitro interactions between new antitubercular drug candidates SQ109 and TMC207.

Reddy VM, Einck L, Andries K, Nacy CA.

Antimicrob Agents Chemother. 2010 Jul;54(7):2840-6. doi: 10.1128/AAC.01601-09. Epub 2010 Apr 12.

13.

Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis.

Nikonenko BV, Reddy VM, Protopopova M, Bogatcheva E, Einck L, Nacy CA.

Antimicrob Agents Chemother. 2009 Jul;53(7):3138-9. doi: 10.1128/AAC.00366-09. Epub 2009 May 4.

14.

Preclinical study of new TB drugs and drug combinations in mouse models.

Nikonenko BV, Sacksteder KA, Hundert S, Einck L, Nacy CA.

Recent Pat Antiinfect Drug Discov. 2008 Jun;3(2):102-16. Review.

PMID:
18673123
15.

In vitro antimycobacterial activities of capuramycin analogues.

Reddy VM, Einck L, Nacy CA.

Antimicrob Agents Chemother. 2008 Feb;52(2):719-21. Epub 2007 Dec 10.

16.

PrimaTB STAT-PAK assay, a novel, rapid lateral-flow test for tuberculosis in nonhuman primates.

Lyashchenko KP, Greenwald R, Esfandiari J, Greenwald D, Nacy CA, Gibson S, Didier PJ, Washington M, Szczerba P, Motzel S, Handt L, Pollock JM, McNair J, Andersen P, Langermans JA, Verreck F, Ervin S, Ervin F, McCombs C.

Clin Vaccine Immunol. 2007 Sep;14(9):1158-64. Epub 2007 Jul 25.

17.

In search of new cures for tuberculosis.

Protopopova M, Bogatcheva E, Nikonenko B, Hundert S, Einck L, Nacy CA.

Med Chem. 2007 May;3(3):301-16. Review.

PMID:
17504204
18.

Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs.

Nikonenko BV, Protopopova M, Samala R, Einck L, Nacy CA.

Antimicrob Agents Chemother. 2007 Apr;51(4):1563-5. Epub 2007 Jan 22.

19.

Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro.

Chen P, Gearhart J, Protopopova M, Einck L, Nacy CA.

J Antimicrob Chemother. 2006 Aug;58(2):332-7. Epub 2006 Jun 3.

PMID:
16751637
20.

Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis.

Bogatcheva E, Hanrahan C, Nikonenko B, Samala R, Chen P, Gearhart J, Barbosa F, Einck L, Nacy CA, Protopopova M.

J Med Chem. 2006 Jun 1;49(11):3045-8.

21.

Design and optimization of a recombinant system for large-scale production of the MPT64 antigen from Mycobacterium tuberculosis.

Geisbrecht BV, Nikonenko B, Samala R, Nakamura R, Nacy CA, Sacksteder KA.

Protein Expr Purif. 2006 Mar;46(1):64-72. Epub 2005 Sep 16.

PMID:
16216527
22.

Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines.

Protopopova M, Hanrahan C, Nikonenko B, Samala R, Chen P, Gearhart J, Einck L, Nacy CA.

J Antimicrob Chemother. 2005 Nov;56(5):968-74. Epub 2005 Sep 19.

PMID:
16172107
23.

Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis.

Nikonenko BV, Samala R, Einck L, Nacy CA.

Antimicrob Agents Chemother. 2004 Dec;48(12):4550-5.

24.

New tuberculosis vaccine development.

Sacksteder KA, Nacy CA.

Expert Opin Biol Ther. 2002 Oct;2(7):741-9. Review.

PMID:
12387673
25.

Detection of active tuberculosis by an MPB-64 transdermal patch: a field study.

Nakamura RM, Einck L, Velmonte MA, Kawajiri K, Ang CF, Delasllagas CE, Nacy CA.

Scand J Infect Dis. 2001;33(6):405-7.

PMID:
11450857
26.

A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer.

Sim BK, O'Reilly MS, Liang H, Fortier AH, He W, Madsen JW, Lapcevich R, Nacy CA.

Cancer Res. 1997 Apr 1;57(7):1329-34.

27.

Interaction of anti-cholesterol antibodies with human lipoproteins.

Dijkstra J, Swartz GM Jr, Raney JJ, Aniagolu J, Toro L, Nacy CA, Green SJ.

J Immunol. 1996 Sep 1;157(5):2006-13.

PMID:
8757321
28.

Growth of Francisella tularensis LVS in macrophages: the acidic intracellular compartment provides essential iron required for growth.

Fortier AH, Leiby DA, Narayanan RB, Asafoadjei E, Crawford RM, Nacy CA, Meltzer MS.

Infect Immun. 1995 Apr;63(4):1478-83.

29.

Nitric oxide: cytokine-regulation of nitric oxide in host resistance to intracellular pathogens.

Green SJ, Scheller LF, Marletta MA, Seguin MC, Klotz FW, Slayter M, Nelson BJ, Nacy CA.

Immunol Lett. 1994 Dec;43(1-2):87-94. Review.

30.
31.

Interleukin-2 suppresses activated macrophage intracellular killing activity by inducing macrophages to secrete TGF-beta.

Nelson BJ, Danielpour D, Rossio JL, Turpin J, Nacy CA.

J Leukoc Biol. 1994 Jan;55(1):81-90.

PMID:
8283143
32.

Life and death of an intracellular pathogen: Francisella tularensis and the macrophage.

Fortier AH, Green SJ, Polsinelli T, Jones TR, Crawford RM, Leiby DA, Elkins KL, Meltzer MS, Nacy CA.

Immunol Ser. 1994;60:349-61. Review. No abstract available.

PMID:
8251580
33.

Macrophage activation: a riddle of immunological resistance.

Crawford RM, Leiby DA, Green SJ, Nacy CA, Fortier AH, Meltzer MS.

Immunol Ser. 1994;60:29-46. Review.

PMID:
8251575
34.
35.

T-cell-independent resistance to infection and generation of immunity to Francisella tularensis.

Elkins KL, Rhinehart-Jones T, Nacy CA, Winegar RK, Fortier AH.

Infect Immun. 1993 Mar;61(3):823-9.

37.

Immunotherapy of tularemia: characterization of a monoclonal antibody reactive with Francisella tularensis.

Narayanan RB, Drabick JJ, Williams JC, Fortier AH, Meltzer MS, Sadoff JC, Bolt CR, Nacy CA.

J Leukoc Biol. 1993 Jan;53(1):112-6.

PMID:
8426087
38.

Detection of Francisella tularensis in blood by polymerase chain reaction.

Long GW, Oprandy JJ, Narayanan RB, Fortier AH, Porter KR, Nacy CA.

J Clin Microbiol. 1993 Jan;31(1):152-4.

39.

Rapid generation of specific protective immunity to Francisella tularensis.

Elkins KL, Leiby DA, Winegar RK, Nacy CA, Fortier AH.

Infect Immun. 1992 Nov;60(11):4571-7.

40.

Introduction of Francisella tularensis at skin sites induces resistance to infection and generation of protective immunity.

Elkins KL, Winegar RK, Nacy CA, Fortier AH.

Microb Pathog. 1992 Nov;13(5):417-21.

PMID:
1297917
41.
42.
43.

In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies.

Leiby DA, Fortier AH, Crawford RM, Schreiber RD, Nacy CA.

Infect Immun. 1992 Jan;60(1):84-9.

44.

Interleukin-2 and the regulation of activated macrophage cytotoxic activities.

Nelson BJ, Belosevic M, Green SJ, Turpin J, Nacy CA.

Adv Exp Med Biol. 1992;319:77-88. Review. No abstract available.

PMID:
1414608
45.

Live vaccine strain of Francisella tularensis: infection and immunity in mice.

Fortier AH, Slayter MV, Ziemba R, Meltzer MS, Nacy CA.

Infect Immun. 1991 Sep;59(9):2922-8.

46.

Cytokines that regulate macrophage production of nitrogen oxides and expression of antileishmanial activities.

Nacy CA, Nelson BJ, Meltzer MS, Green SJ.

Res Immunol. 1991 Sep;142(7):573-6. No abstract available.

PMID:
1812551
47.

Cytokine-induced synthesis of nitrogen oxides in macrophages: a protective host response to Leishmania and other intracellular pathogens.

Green SJ, Nacy CA, Meltzer MS.

J Leukoc Biol. 1991 Jul;50(1):93-103. Review. No abstract available.

PMID:
2056250
48.

T-cell-mediated activation of macrophages.

Nacy CA, Meltzer MS.

Curr Opin Immunol. 1991 Jun;3(3):330-5. Review.

PMID:
1910612
49.
50.

Supplemental Content

Support Center